(Total Views: 473)
Posted On: 05/10/2021 1:15:48 PM
Post# of 155002
Here's One of Them... The argument is that some compound that doesn't work is somehow competing with LLMab.
Nader said in the interview that they will be pricing LLMab in relation to whatever else is treating critical covid patients and the goal is to make it accessible.. but guess what?
There isn't anything that successfully treats critical covid, at any price.
Guess you get to name your price, Nader.
And Gilead can charge 10¢ for something that, ounce for ounce, works about as well as baking soda.
Nader said in the interview that they will be pricing LLMab in relation to whatever else is treating critical covid patients and the goal is to make it accessible.. but guess what?
There isn't anything that successfully treats critical covid, at any price.
Guess you get to name your price, Nader.
And Gilead can charge 10¢ for something that, ounce for ounce, works about as well as baking soda.
Quote:
Posted On: 05/10/2021 11:37:41 AM
Post#
89597
of 89618
Posted By: MD VIROLOGIST
For those interested this is the DOH of PI recommendation for pricing of redemsivir:
https://cnnphilippines.com/news/2021/4/24/doh
(3)
(0)
